Delpacibart zotadirsen is under clinical development by Avidity Biosciences and currently in Phase II for Duchenne Muscular Dystrophy. According to GlobalData, Phase II drugs for Duchenne Muscular Dystrophy have a 61% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Delpacibart zotadirsen’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Delpacibart zotadirsen overview
AOC-1044 is under development for the treatment of Duchenne muscular dystrophy. The drug candidate is an antibody oligonucleotide conjugate (AOC) comprising monoclonal antibody that binds to the transferrin receptor 1 (TfR1) conjugated with phosphorodiamidate morpholino oligomer (PMO) targeting exon 44 of dystrophin mRNA. It is being developed based on antibody oligonucleotide conjugate (AOC) platform.
Avidity Biosciences overview
Avidity Biosciences is a biotechnology company that focuses on the development of RNA therapeutics. The company’s primary activities focuses on the creation and advancement of its proprietary antibody oligonucleotide conjugates (AOC) platform, that combines the specificity of monoclonal antibodies with the precision of oligonucleotides. Avidity Biosciences‘ major products include AOC programs for rare diseases such as myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and duchenne muscular dystrophy (DMD). Its products are primarily used in the healthcare industry, specifically in the treatment of muscle diseases. The company operates in the US. Avidity Biosciences is headquartered in San Diego, California, the US.
For a complete picture of Delpacibart zotadirsen’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
